Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 11, 2026, 5:05 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 2137–2160 of 3,925 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: HTN Clear all

Conditions: Chronic Pain, Hypertension, Diuretics Drug Reactions, SCS
Interventions: Hydrochlorothiazide 12.5mg, Placebo; Drug
Lead sponsor: University of Kansas Medical Center; Other
Eligibility: 40 Years to 79 Years
Enrollment: 36 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2027
U.S. locations: 1
States / cities: Kansas City, Kansas

Conditions: Pulmonary Arterial Hypertension
Interventions: Treprostinil Palmitil Inhalation Powder, Placebo; Drug
Lead sponsor: Insmed Incorporated; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 344 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2029
U.S. locations: 11
States / cities: Los Angeles, California • Santa Barbara, California • Torrance, California + 7 more

Conditions: Open Angle Glaucoma, Ocular Hypertension
Interventions: NCX 470 0.065% (initial phase of trial), Latanoprost 0.005% (initial phase of trial), NCX 470 0.1% (initial phase of trial), NCX 470 0.1% (remainder of trial), Latanoprost 0.005% (remainder of trial); Drug
Lead sponsor: Nicox Ophthalmics, Inc.; Industry
Eligibility: 18 Years to 84 Years
Enrollment: 691 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2022
U.S. locations: 1
States / cities: Newport Beach, California

Conditions: Endothelial Dysfunction
Interventions: Sapropterin Dihydrochloride, Sapropterin Dihydrochloride and Vitamin C; Drug
Lead sponsor: BioMarin Pharmaceutical; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 52 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2009
U.S. locations: 1
States / cities: Hackensack, New Jersey

Conditions: Cognitively Normal Older Adults, Hypertension, Subjective Cognitive Decline, Family History of Dementia
Interventions: Angiotensin II Receptor Blockers (ARBs, losartan) and Calcium Channel Blockers (CCB, amlodipine), PCP; Drug · Other
Lead sponsor: Rong Zhang; Other
Eligibility: 60 Years to 85 Years
Enrollment: 180 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2028
U.S. locations: 1
States / cities: Dallas, Texas

Conditions: Allogeneic Stem Cell Transplantation, Lung Allograft Transplantation, Interstitial Lung Disease, Acute Lung Injury, Pulmonary Arterial Hypertension, Cardiovascular Diseases
Interventions: [18F]FAPI-74, 18F-FAPI-74 PET/CT Imaging; Drug · Diagnostic Test
Lead sponsor: National Heart, Lung, and Blood Institute (NHLBI); NIH
Eligibility: 18 Years to 100 Years
Enrollment: 210 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2033
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Glaucoma, Open-Angle
Interventions: Netarsudil Ophthalmic; Drug
Lead sponsor: University of the Incarnate Word; Other
Eligibility: 18 Years and older
Enrollment: 10 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020 – 2021
U.S. locations: 1
States / cities: San Antonio, Texas

Conditions: Difficult to Control Hypertension
Interventions: MANP, Placebo Matched control; Drug · Other
Lead sponsor: E-Star BioTech, LLC; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 120 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2027
U.S. locations: 23
States / cities: Little Rock, Arkansas • Lake Forest, California • Westlake Village, California + 19 more

Conditions: Glaucoma
Interventions: Trabeculectomy with mitomycin c, Ex-Press mini shunt with mitomycin c; Procedure
Lead sponsor: Indiana University; Other
Eligibility: 18 Years and older
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2010
U.S. locations: 1
States / cities: Indianapolis, Indiana

Conditions: Pulmonary Arterial Hypertension
Interventions: Intestinal microbiota transplant (IMT); Drug
Lead sponsor: University of Minnesota; Other
Eligibility: 18 Years to 75 Years
Enrollment: 11 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2023
U.S. locations: 1
States / cities: Minneapolis, Minnesota

Conditions: Glaucoma, Open-Angle
Interventions: Latanoprost 0.005%, Latanoprost bunod 0.024%, Normal saline 0.9%, Nailfold capillaroscopy; Drug · Diagnostic Test
Lead sponsor: Icahn School of Medicine at Mount Sinai; Other
Eligibility: 40 Years to 80 Years
Enrollment: 47 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2020
U.S. locations: 1
States / cities: New York, New York

Conditions: Essential Hypertension
Interventions: Aprocitentan 5 mg, Aprocitentan 10 mg, Aprocitentan 25 mg, Aprocitentan 50 mg, Lisinopril 20 mg, Placebo; Drug
Lead sponsor: Idorsia Pharmaceuticals Ltd.; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 1,659 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2017
U.S. locations: 74
States / cities: Fort Payne, Alabama • Chandler, Arizona • Peoria, Arizona + 62 more

Conditions: Glaucoma, Open-Angle, Ocular Hypertension
Interventions: Bimatoprost SR, Sham Bimatoprost SR, Selective Laser Trabeculoplasty, Sham Selective Laser Trabeculoplasty; Drug · Procedure
Lead sponsor: AbbVie; Industry
Eligibility: 18 Years and older
Enrollment: 240 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2023
U.S. locations: 51
States / cities: Dothan, Alabama • Glendale, Arizona • Phoenix, Arizona + 43 more

Conditions: Pulmonary Arterial Hypertension
Interventions: Macitentan 10 mg, Placebo; Drug
Lead sponsor: Actelion; Industry
Eligibility: 12 Years and older
Enrollment: 226 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2016
U.S. locations: 7
States / cities: Los Angeles, California • Palo Alto, California • Atlanta, Georgia + 4 more

Conditions: Prehypertension, Gout, Pulse Wave Velocity, Hypertension, 24 Hour Blood Pressure
Interventions: Febuxostat; Drug
Lead sponsor: University of California, San Diego; Other
Eligibility: 18 Years to 50 Years
Enrollment: 47 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2011 – 2014
U.S. locations: 1
States / cities: San Diego, California

Conditions: Glaucoma
Interventions: Rocklatan eye drops will be instilled nightly in one eye diagnosed with glaucoma for up to 12 months., Two optical coherence tomography (OCT) devices will be used to assess blood flow changes.; Drug · Device
Lead sponsor: Oregon Health and Science University; Other
Eligibility: 21 Years and older
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2027
U.S. locations: 1
States / cities: Portland, Oregon

Conditions: Hypertension, Primary Care
Interventions: Provider nudge, Patient nudge, Pharmacist Virtual Visit; Behavioral
Lead sponsor: Brigham and Women's Hospital; Other
Eligibility: 18 Years to 80 Years
Enrollment: 720 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2027
U.S. locations: 1
States / cities: Milwaukee, Wisconsin

Conditions: Prehypertension, Hypertension, Blood Pressure
Interventions: Health Education, Individual-Level Peer Support, Community-Level Peer Support; Behavioral
Lead sponsor: University of Alabama at Birmingham; Other
Eligibility: 19 Years and older
Enrollment: 416 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2026
U.S. locations: 1
States / cities: Birmingham, Alabama

Conditions: Uncontrolled Hypertension
Interventions: Primer postcard, Control recruitment letter, Behavioral theory-informed recruitment letter, 2 phone calls, 4 phone calls; Behavioral
Lead sponsor: Columbia University; Other
Eligibility: 18 Years and older
Enrollment: 584 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2027
U.S. locations: 1
States / cities: New York, New York

Conditions: Blood Pressure
Interventions: Clinic Blood Pressure Measurement, Home Blood Pressure Measurement, Kiosk Blood Pressure Measurement, 24-hour Ambulatory Blood Pressure Monitoring (Reference Standard); Diagnostic Test
Lead sponsor: Kaiser Permanente; Other
Eligibility: 18 Years to 85 Years
Enrollment: 510 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017 – 2019
U.S. locations: 1
States / cities: Seattle, Washington

Conditions: Hypertension, Medication Adherence
Interventions: Medication Reminder App; Device
Lead sponsor: Washington University School of Medicine; Other
Eligibility: 18 Years and older
Enrollment: 41 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2024
U.S. locations: 1
States / cities: St Louis, Missouri

Conditions: Hypertension
Interventions: COREG CR and lisinopril (FDC); Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 24 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2007
U.S. locations: 1
States / cities: Austin, Texas

Conditions: Anxiety, Wellness, Psychological, Overweight or Obesity, Hypertension, Prehypertension, Low Physical Fitness
Interventions: Fit2Lead Group 1-2; Behavioral
Lead sponsor: Duke University; Other
Eligibility: 12 Years to 17 Years
Enrollment: 1,000 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2016 – 2028
U.S. locations: 1
States / cities: Miami, Florida

Conditions: Hypertension (HTN), Cardiometabolic Diseases
Interventions: Low Salt Diet, High Salt Diet, Saline Infusion; Dietary Supplement
Lead sponsor: University of Alabama at Birmingham; Other
Eligibility: 18 Years and older
Enrollment: 200 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2026 – 2030
U.S. locations: 1
States / cities: Birmingham, Alabama

Search by objective public record fields.

Improving Pain Management Via Spinal Cord Stimulation and Blood Pressure Reduction

A Study to Evaluate the Efficacy and Safety of Once Daily Treprostinil Palmitil Inhalation Powder (TPIP) in Participants With Pulmonary Arterial Hypertension (PAH)

Phase 3 Trial of NCX 470 vs. Latanoprost in Subjects With Open-Angle Glaucoma or Ocular Hypertension

A Phase 2, Pharmacokinetic (PK) Study of 6R-BH4 Alone or 6R-BH4 With Vitamin C in Subjects With Endothelial Dysfunction

Impact of Intensive Treatment of SBP on Brain Perfusion, Amyloid, and Tau (IPAT Study)

Fibrotic Disease Activity in Cardiopulmonary Disorders Using 18F-Fibroblast Activation Protein Inhibitor (18F-FAPI-74) PET/CT Imaging

Short-term Effect of Rho-kinase Inhibitor on Retinal Circulation

To Evaluate the Safety and Efficacy of MANP in Subjects With Difficult to Control/ Resistant Hypertension

A Clinical Study Comparing the Inflammatory Response of the Ex-Press Mini Shunt to Trabeculectomy

Microbiota Transplant Therapy for Pulmonary Arterial Hypertension: Early Safety and Feasibility Study

Nailfold Capillary Blood Flow With Latanoprost Bunod

Dose-finding Study With ACT-132577 (Aprocitentan) in Participants With Essential Hypertension

Comparison of Bimatoprost Sustained Release (SR) to Selective Laser Trabeculoplasty (SLT) in Adults With Open-Angle Glaucoma or Ocular Hypertension

Clinical Study to Evaluate the Effects of Macitentan on Exercise Capacity in Subjects With Eisenmenger Syndrome

Study of Febuxostat Effect on Blood Pressure in Patients With High Normal Blood Pressure

Rocklatan Retinal Perfusion OCT Study

Fixed-Dose Combinations Pragmatic Randomized Implementation Trial for Blood Pressure Control

Equity in Prevention and Progression of Hypertension by Addressing Barriers to Nutrition and Physical activitY

Engaging Patients in Adherence Interventions Using Behavioral Science

Blood Pressure Checks for Diagnosing Hypertension (BP-CHECK)

Pill Bottle vs Reminder App

Study to Examine the Effect of Food on the Pharmacokinetics of the Fixed Dose Combination of COREG CR and Lisinopril.

Community Park-Based Programs for Health Promotion: The Fit2Lead Prospective Cohort Study

Genetic Architecture of Natriuretic Peptides and Blood Pressure Response